Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enanta Pharmaceuticals

6.30
+0.20003.28%
Volume:278.22K
Turnover:1.72M
Market Cap:134.40M
PE:-1.27
High:6.32
Open:5.97
Low:5.93
Close:6.10
Loading ...

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Zacks
·
23 Dec 2024

Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy Buchanan

TIPRANKS
·
13 Dec 2024

Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)

TIPRANKS
·
11 Dec 2024

Enanta Pharmaceuticals’ RSV Platform Advances: Buy Rating Affirmed on Promising Clinical Data

TIPRANKS
·
10 Dec 2024

Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus

MT Newswires Live
·
09 Dec 2024

Enanta announces ‘positive’ results from Phase 2 study of zelicapavir

TIPRANKS
·
09 Dec 2024

Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials

Dow Jones
·
09 Dec 2024

BRIEF-Enanta Pharmaceuticals Announces Positive Phase 2 Results Evaluating Zelicapavir

Reuters
·
09 Dec 2024

Enanta Pharmaceuticals Announces Positive Topline Results From First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (Rsv)

THOMSON REUTERS
·
09 Dec 2024

Enanta Pharmaceuticals Inc - Antiviral Effect Observed With 1.4 Log Viral Load Decline in Part 2

THOMSON REUTERS
·
09 Dec 2024

Enanta Pharmaceuticals Inc - Zelicapavir Well-Tolerated With Favorable Safety Profile

THOMSON REUTERS
·
09 Dec 2024

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Business Wire
·
09 Dec 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Business Wire
·
07 Dec 2024

Enanta Pharmaceuticals (ENTA) Receives a Sell from J.P. Morgan

TIPRANKS
·
28 Nov 2024

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility

TIPRANKS
·
28 Nov 2024

Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $14 From $16, Maintains Perform Rating

MT Newswires Live
·
27 Nov 2024